STOCK TITAN

Heron Therapeutics (HRTX) CEO exercises 62,500 RSUs into common stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Heron Therapeutics Chief Executive Officer Craig A. Collard exercised 62,500 restricted stock units into 62,500 shares of common stock. The RSUs carried a $0.0000 exercise price and each unit represented a right to receive one share of common stock.

After the transaction, Collard directly owned 648,255 shares of Heron Therapeutics common stock. His holdings include 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025. The restricted stock units vest in four equal annual installments beginning one year after the grant date, contingent on his continued service.

Positive

  • None.

Negative

  • None.
Insider Collard Craig A
Role Chief Executive Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 62,500 $0.00 --
Exercise Common Stock 62,500 $0.00 --
Holdings After Transaction: Restricted Stock Units — 62,500 shares (Direct); Common Stock — 648,255 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of common stock. Includes 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025. The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.
RSUs exercised 62,500 units Restricted stock units converted to common stock on 2026-04-03
Shares received from RSUs 62,500 shares Common stock received from RSU exercise on 2026-04-03
Exercise price $0.0000 per share Price for conversion of restricted stock units
Post-transaction holdings 648,255 shares Common stock directly owned after transactions
ESPP shares included 14,045 shares Acquired under 1997 Employee Stock Purchase Plan on 2025-04-30
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Purchase Plan financial
"Includes 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
vest financial
"The restricted stock units vest in four equal annual installments beginning one year after the date of grant."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
derivative security financial
"Transaction code M is described as Exercise or conversion of derivative security."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Collard Craig A

(Last)(First)(Middle)
100 REGENCY FOREST DRIVE
SUITE 300

(Street)
CARY NORTH CAROLINA 27518

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/03/2026M62,500A(1)648,255(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$004/03/2026M62,500 (3) (3)Common Stock62,500$062,500D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. Includes 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025.
3. The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.
/s/Kathryn Lester Attorney-in-fact for Craig Collard04/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Heron Therapeutics (HRTX) CEO Craig Collard report in this Form 4?

Craig Collard reported exercising 62,500 restricted stock units, receiving 62,500 shares of Heron Therapeutics common stock at a $0.0000 exercise price. Following this transaction, he directly held 648,255 shares, reflecting compensation-related equity rather than an open-market share purchase or sale.

How many Heron Therapeutics (HRTX) shares does the CEO hold after this transaction?

After the reported transactions, CEO Craig Collard directly owns 648,255 shares of Heron Therapeutics common stock. This total includes shares obtained from restricted stock units, as well as 14,045 shares previously acquired under the company’s 1997 Employee Stock Purchase Plan on April 30, 2025.

What are the details of the 62,500 restricted stock units exercised at Heron (HRTX)?

The filing shows 62,500 restricted stock units exercised, converting into 62,500 shares of common stock at a $0.0000 exercise price. Each restricted stock unit represents a contingent right to receive one share of common stock, reflecting stock-based compensation rather than a cash-funded stock purchase.

How do Craig Collard’s restricted stock units at Heron (HRTX) vest?

The restricted stock units vest in four equal annual installments, beginning one year after the grant date. Vesting is conditioned on Craig Collard’s continued service to Heron Therapeutics through each vesting date, aligning his long-term incentives with ongoing employment at the company.

What role did the Heron 1997 Employee Stock Purchase Plan play in these holdings?

A footnote explains that Collard’s holdings include 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025. This plan allows eligible employees to purchase company stock, adding to his overall equity position beyond restricted stock units.

Does this Heron (HRTX) Form 4 show any open-market buying or selling by the CEO?

The Form 4 reflects an exercise or conversion of derivative securities, not open-market trades. Transaction code M and the $0.0000 price indicate a derivative exercise of restricted stock units into common shares, with no reported open-market buying or selling of Heron stock in this filing.